Johns Hopkins School of Medicine, Department of Biophysics and Biophysical Chemistry, 725 N. Wolfe Street, Baltimore, MD 21202, United States.
Curr Opin Struct Biol. 2010 Aug;20(4):489-96. doi: 10.1016/j.sbi.2010.06.003. Epub 2010 Jun 26.
Multidrug resistance (MDR) mechanisms provide responses that sense and extrude arrays of diverse drugs from cellular environments. To do this, MDR functions rely on two linked features--multidrug recognition (MD) and allosteric linkages to drug binding. Crystal structures of drug-bound BmrR and QacR complexes offered the first insights into the details of drug recognition and the canonical view of MD recognition. Recent structural reports provide further support for the canonical theme as well as variations thereof. Multiple drug-bound TtgR and BmrR structures facilitate proposals of binding models, which agree with promiscuous binding and drug-binding profiles. Significantly, the canonical view may be a useful framework to guide future structural interpretations and model proposals. This will be important as alternative depictions of MD recognition become available through more structure determinations.
多药耐药(MDR)机制提供了对细胞环境中多种药物的感应和外排的反应。为此,MDR 功能依赖于两个关联特征——多药识别(MD)和药物结合的变构连接。结合药物的 BmrR 和 QacR 复合物的晶体结构首次提供了对药物识别细节和 MD 识别的规范观点的深入了解。最近的结构报告为规范主题及其变体提供了进一步的支持。多个结合药物的 TtgR 和 BmrR 结构促进了结合模型的提出,这些模型与混杂结合和药物结合谱一致。重要的是,规范观点可能是一个有用的框架,可用于指导未来的结构解释和模型建议。随着更多结构测定的出现,MD 识别的替代描述变得可用,这将非常重要。